851445-82-4

Upstream product

• 13096-62-3 (3R,4S,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-one 
• 191863-31-7 2,3,4,6-tetra-O-benzyl-1,5-dideoxy-1-[(2',2'-dimethoxyethyl)imino]-1,5-imino-D-glucitol 
• 4291-69-4 2,3,4,6-Tetra-O-benzyl-D-glucopyranose 
• 77174-08-4 (3R,4S,5R,6R)-3,4,5-tris(benzyloxy)-6-(benzyloxymethyl)piperidin-2-one 
• 76670-93-4 2,3,4,6-tetra-O-benzyl-D-gluconamide 
• 76670-94-5 2,3,4,6-tetra-O-benzyl-5-dehydro-5-oxo-D-gluconamide 
• 153996-70-4 2,3,4,6-tetra-O-benzyl-D-glucono-δ-thiolactam 
• 191863-33-9 (5R,6R,7S,8S)-6,7,8-tris(benzyloxy)-5-[(benzyloxy)-methyl]-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine 
• 97-30-3 methyl-alpha-D-glucopyranoside 
• 244138-64-5 (5R,6R,7S,8S)-6,7,8-tris(benzyloxy)-5-[(benzyloxy)methyl]-2-iodo-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine 
• 263719-95-5 (5R,6R,7S,8S)-6,7,8-tris(benzyloxy)-5-[(benzyloxy)methyl]-2,3-diiodo-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine 

Relevant academic research and scientific papers

Structure-activity relationships in a series of C2-substituted gluco-configured tetrahydroimidazopyridines as β-glucosidase inhibitors

Inhibition of glycoside hydrolases has widespread application in treatment of diabetes, viral infections, lysosomal storage diseases and cancers. Gluco-configured tetrahydroimidazopyridines are the most potent β-glucosidase inhibitors reported to date. Using transition state mimic strategy, a series of C2-substituted gluco-configured tetrahydroimidazopyridines were designed and synthesized. Compounds 3 (Ki = 0.64 nM) and 5 (Ki = 0.58 nM) showed stronger inhibitory potency against β-glucosidase. Maestro 9.1 was used to study the structure-activity relationships by docking the compounds into the β-glucosidase active sites. Crown Copyright

METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE

Provided is a method of increasing the stability of wild-type β- glucocerebrosidase. Also provided are methods of treating and/or preventing an individual having a neurological disease in which increased expression or activity of β-glucocerebrosidase in the central nervous system would be beneficial. This method comprises administering an effective amount of a pharmacologic chaperone for β- glucocerebrosidase, with the proviso that the individual does not have a mutation in the gene encoding β-glucocerebrosidase. Further provided are β-glucocerebrosidase inhibitors which have been identified as specific pharmacologic chaperones and which have been shown to increase activity of β-glucocerebrosidase in vivo in the central nervous system.

GLUCOIMIDAZOLE AND POLYHYDROXYCYCLOHEXENYL AMINE DERIVATIVES TO TREAT GAUCHER DISEASE

The present invention provides glucoimidazole (GIZ) and polyhydroxycyclohexenyl amine (PHCA) derivatives, methods of making them, and methods of use where the GIZ and PHCA derivatives have a short, flexible linker emanating from the corresponding position